Description

FOXO4-DRI (Proxofim) – Product Information

• FOX04-DRI (Proxofim) is offered in 10mg lyophilized powder.
• In the context of research, it is advisable to opt for bacteriostatic water when reconstituting substances rather than sterile water.

What is FOXO4-DRI (Proxofim)?

FOXO4-D-Retro-Inverso is a cell-penetrating peptide that has been shown to cause senescent cells to die by apoptosis.

Forkhead box protein O4 (FOXO4) is a transcription factor that regulates multiple genes involved in apoptosis, cell cycle regulation(cell metabolism), and cellular homeostasis among other processes. FOXO4 plays a crucial role in the transcriptional regulation of diverse tissues and organs leading to improved organ function and influencing the onset and progression of numerous diseases.

There are peptide sciences that could change the way we treat diseases. It works by going after specific proteins, which makes it easier to treat diseases more precisely. Foxo4 can help reduce inflammation and increase cell survival by focusing on these proteins.

It has been used to treat everything from cancer to multiple sclerosis, and scientists are just starting to find out what else it can do. Foxo4 could help treat a wide range of medical problems if more research can be proven.

FOXO4-DRI (Proxofim)
CAS Number
Molar Mass	5358.05 g/mol
Chemical Formula	C228H388N86O64
IUPAC Name	H-Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH

What is -DRI?

Peptides containing d amino acids have advantages over those containing only l amino acids. Peptides that are constructed from D-amino acids are resistant to enzymatic breakdown. Because of this, these are excellent candidates for the development of medications because their biological action lasts for far longer.

D- retro inverso peptides are of particular interest because they are produced by inverting the amino acid sequence of D-amino acids. This results in molecules that have nearly the same structure, stability, and bioactivity as their parent L-peptides, but with increased resistance to proteolytic degradation. [R]

How Does FOXO4-DRI Work?

In senescent cells, the FOXO4 protein is identified as a key regulator of p53 function. As a major regulator of apoptosis and cell senescence, the p53 pathway is a potential senolytic therapeutic target. It was hypothesized that FOXO4 would bind to p53 and suppress p53-targeted apoptosis.

By creating the interfering peptide FOXO4-DRI, which competes with natural FOXO4 for p53 binding, the study demonstrated that selective apoptosis could be triggered in both aging and chemotherapy-induced senescent cells.[R]

FOXO4-DRI Research:

Numerous animal subjects and human studies have been conducted on the potential application of FOXO4-DRI. Following are some of the relevant findings for educational and scientific research :

FOXO4-DRI Senolytic Peptide on Senescent Cells

A study investigated the use of FOXO4-DRI as a senolytic peptide, which is a substance that can target and remove senescent cells. The study was conducted in vitro (in a laboratory setting) using human chondrocytes (cartilage cells). The results showed that FOXO4-DRI was able to selectively remove senescent cells from the human chondrocytes.

This research suggests that FOXO4-DRI has potential as a senolytic peptide, but it is important to note that these results are limited to a laboratory setting and more research is needed to determine its effects in healthy cells of living organisms and safety for human consumption. [R]

FOXO4-DRI on Senescent Cancer Cells

The studies showed the potential use of FOXO4-DRI as a senolytic peptide for the elimination of senescent cancer cells. Senescent cells are cells that have stopped dividing and have ceased to be capable of proliferating but are not dead. They accumulate with aging and in various disease states and have been implicated in the aging process.

The study used molecular modeling to investigate the interaction between FOXO4 and TP53, two proteins that play a role in the aging process and cancer. The results of the study suggest that FOXO4-DRI may have the potential, as a senolytic peptide for the elimination of senescent cancer cells by modulating the interaction between FOXO4 and TP53.

However, it is important to note that this research was performed using computer simulations. More research or clinical trials, including animal and human studies, are needed to determine the potential effectiveness and safety of FOXO4-DRI as a senolytic peptide for the elimination of senescent cancer cells.[R]

FOXO4-DRI on Age-related Diseases (Testosterone Secretion)

Research studies were published to understand the impact of FOXO4-DRI on testosterone secretion in aged mice. By targeting senescent Leydig cells, the study discovered that FOXO4-DRI helped older mice with testosterone secretion issues. This data implies that FOXO4-DRI could be a useful therapeutic tool for treating low testosterone levels caused by aging.

To assess the possible effects and safety of FOXO4-DRI in people, more research, including human studies, is required. The results of this study were obtained using mice – further study is needed for human models. [R]

FOXO4-DRI on Chemotoxicity and Aging

According to the findings of a study, restoring tissue homeostasis in response to chemotoxicity and the effects of aging can be accomplished through the targeted apoptosis of senescent cells. This lends credence to the hypothesis that addressing conditions associated with chemotoxicity and aging, through the use of targeted apoptosis of senescent cells may have the potential to yield beneficial effects.

This study did not go into detail regarding the precise mechanism by which FOXO4-DRI functions as a senolytic peptide. It is necessary to conduct additional research, including studies that specifically investigate the effects and mode of action of FOXO4-DRI, in order to determine its potential benefits and the mechanism by which it operates. [R]

FOXO4-DRI on Pulmonary Fibrosis

A study is conducted to know the effects of a FOXO4 peptide on myofibroblast and its ability to ameliorate bleomycin-induced pulmonary fibrosis in mice through the ECM-receptor interaction pathway. The study found that the FOXO4 peptide targeted myofibroblast and ameliorated bleomycin-induced pulmonary fibrosis in mice through the ECM-receptor interaction pathway.

More research is needed to determine the potential benefits and mode of action of FOXO4-DRI in relation to pulmonary fibrosis or any other condition.

FOXO4-DRI on Colorectal Cancer

The study looked at the role of the transcription factor FOXO4 in the migration and metastasis of colorectal cancer and how it controls the APC2/-Catenin axis. The study found that the APC2/-Catenin axis is controlled by FOXO4, which stops colorectal cancer cells from moving and spreading.

It is important to remember that this study looked at the effects of FOXO4, not FOXO4-DRI. More scientific research is needed to figure out the possible benefits of FOXO4-DRI and how it might work to treat colorectal cancer or any other disease. [R]

FOXO4-DRI on Heart Attack

Myocardial infarction is another name for a heart attack, which occurs when a portion of the heart muscle dies because it is deprived of blood supply. Studies have demonstrated that activation of FOXO4 in the endothelial cells of blood vessels following a heart attack increases the expression of Arg1, which in turn contributes to the early inflammatory response that occurs in the heart tissue.

This early inflammatory response is thought to play a role in the development of cardiac disease and heart failure following a heart attack. OXO4-DRI peptide might boost the body’s natural process and eliminate all the dysfunctional cells (Therapeutic Elimination), which in turn may help prevent the occurrence of age-related heart diseases

Therefore, FOXO4 is considered to be a potential therapeutic target for treating the early inflammatory response following a heart attack and improving outcomes in patients with this condition. By blocking the activity of FOXO4 or targeting the pathways it regulates, it may be possible to reduce the early inflammatory response and improve heart function following a heart attack.[R]

FOXO4-DRI on Diabetes mellitus

Diabetes mellitus is a term that refers to a range of conditions that impact the way in which the body consumes blood sugar (glucose). Its associated complications are a leading cause of mortality worldwide. FOXO4 acts as a vital regulator of diabetes, given its close association with cellular metabolism. Studies have shown that in diabetes mellitus, there is an alteration in the acetylation status of FOXO4, which regulates its activity.

This altered acetylation of FOXO4 has been shown to contribute to the selectively induced apoptosis (cell death) of podocytes, which can lead to kidney damage and further complications in individuals with diabetes mellitus.

Therefore, FOXO4 is considered to be a potential therapeutic target for treating kidney damage in individuals with diabetes mellitus. By blocking the activity of FOXO4 or targeting the pathways it regulates, it may be possible to prevent or reduce the apoptosis of podocytes and improve kidney function in individuals with diabetes mellitus. The mRNA level of FOXO4 was found

However, further studies are necessary to confirm these findings and determine the most effective dose and method of administration. [R]

FOXO4-DRI on Alzheimer’s disease and Parkinson’s disease (neurodegenerative diseases)

Aging can be thought of as the gradual loss of function of the body’s systems, which is a direct result of time passing. This decline is the most important risk factor for age-related diseases like cancer, heart disease, and dementia. Studies have shown that in various species, including humans, the activity of FOXO proteins declines with age, which can contribute to cellular dysfunction, increased oxidative stress, and the development of age-related diseases.

Conversely, increasing the activity of FOXO proteins has been shown to improve cellular function and promote longevity in various organisms. A study has suggested that FOXO4 plays an important role in cellular senescence in the central nervous system, by governing the antioxidant capacity of cells.

Aging is the major predictor for developing multiple neurodegenerative diseases, including Alzheimer’s disease (AD) other dementias, and Parkinson’s disease (PD). Senescent cells, which can drive aging phenotypes, accumulate at etiological sites of many age-related chronic diseases. Foxo4 plays an important role in the development and maintenance of the central nervous system.

However, further studies are necessary to confirm the effect of different neurodegenerative disorders on aged cells. [R]

FOXO4-DRI on Oxidative Stress

Oxidative stress is when your body has too many free radicals and not enough antioxidants. In the same way as other FOXO proteins, one of the most important things FOXO4 does is help cells respond to oxidative stress. On the one hand, reactive oxidative species (ROS) control the activity of FOXO4 by activating the upstream FOXO4 regulatory pathways or by detecting the cellular redox potential.

On the other hand, FOXO4 controls the oxidative state of cells by promoting detoxification through transcriptional activation of antioxidative enzymes like superoxide dismutase 2 (SOD2) and catalase. [R]

FOXO4-DRI on Renal and Urinary tract

The study focuses on the impact of a gene called FOXO4 on cellular senescence in the renal and urinary tract. Cellular senescence is a process in which cells stop dividing and can no longer perform their normal functions, which can contribute to various diseases, including renal and urinary tract disorders.

It is important to note that the results of this study may not be directly applicable to all individuals and that more research is needed to fully understand the effects of FOXO4 on cellular senescence in the renal and urinary tract.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR LABORATORY AND RESEARCH USE ONLY.

All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis and research from Trusted Sources before making any purchase, based on your personal circumstances. You should independently research and verify any information that you find on our Website and wish to rely upon.

By completing and paying for your order, you agree to our Terms and Conditions. Customer satisfaction is our number one priority. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human usage. Stock is subject to availability.